APO RESEARCH · REPORT
Somatostatin
Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.
Product & engineering
Understand the product.
Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.
Selected research
Industry Research
Somatostatin Industry Research Report 2026
Market perspective
Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin.
Global Somatostatin key players include Merck (Schweiz) AG, SANOFI-AVENTIS FRANCE, Lyomark Pharma GmbH, ALFA WASSERMANN S.p.A., HYBIO, etc. Global top five manufacturers hold a share over 65%.
China is the largest market, followed by Europe and India.
Read the full market overview
Report Scope
This report quantifies the global Somatostatin market in terms of revenue (US$ million) and, where applicable, sales volume (K Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Somatostatin Market by Company
Merck (Schweiz) AG
SANOFI-AVENTIS FRANCE
Lyomark Pharma GmbH
ALFA WASSERMANN S.p.A.
Polypeptide Laboratories, Inc
SAMARTH
UBPL
HYBIO
TianTaiShan
Yangtze River
Siyao
Shuangcheng
Hainan Zhonghe
SL PHARM
Wuhan Hualong
Qingdao Guoda
Chengdu Shengnuo
Longjin
Somatostatin Segment by Type
0.25mg/pcs
0.75mg/pcs
3mg/pcs
Somatostatin Segment by Application
Hormonal Disorder
Oncology
Metabolic Disorder
Others
Somatostatin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Somatostatin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Somatostatin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Somatostatin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Somatostatin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.25mg/pcs
- 0.75mg/pcs
- 3mg/pcs
Applications
- Hormonal Disorder
- Oncology
- Metabolic Disorder
- Others
Companies covered
- Merck (Schweiz) AG
- SANOFI-AVENTIS FRANCE
- Lyomark Pharma GmbH
- ALFA WASSERMANN S.p.A.
- Polypeptide Laboratories, Inc
- SAMARTH
- UBPL
- HYBIO
- TianTaiShan
- Yangtze River
- Siyao
- Shuangcheng
- Hainan Zhonghe
- SL PHARM
- Wuhan Hualong
- Qingdao Guoda
- Chengdu Shengnuo
- Longjin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Somatostatin Market Size (2021-2032)
- 2.2.2 Global Somatostatin Sales (2021-2032)
- 2.2.3 Global Somatostatin Market Average Price (2021-2032)
- 2.3 Somatostatin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.25mg/pcs
- 2.3.3 0.75mg/pcs
- 2.3.4 3mg/pcs
- 2.4 Somatostatin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hormonal Disorder
- 2.4.3 Oncology
- 2.4.4 Metabolic Disorder
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Somatostatin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Somatostatin Sales (K Pcs) of Manufacturers (2021-2026)
- 3.3 Global Somatostatin Revenue of Manufacturers (2021-2026)
- 3.4 Global Somatostatin Average Price by Manufacturers (2021-2026)
- 3.5 Global Somatostatin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Somatostatin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Somatostatin, Product Type & Application
- 3.8 Global Manufacturers of Somatostatin, Established Date
- 3.9 Global Somatostatin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck (Schweiz) AG
- 4.1.1 Merck (Schweiz) AG Company Information
- 4.1.2 Merck (Schweiz) AG Business Overview
- 4.1.3 Merck (Schweiz) AG Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck (Schweiz) AG Somatostatin Product Portfolio
- 4.1.5 Merck (Schweiz) AG Recent Developments
- 4.2 SANOFI-AVENTIS FRANCE
- 4.2.1 SANOFI-AVENTIS FRANCE Company Information
- 4.2.2 SANOFI-AVENTIS FRANCE Business Overview
- 4.2.3 SANOFI-AVENTIS FRANCE Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 SANOFI-AVENTIS FRANCE Somatostatin Product Portfolio
- 4.2.5 SANOFI-AVENTIS FRANCE Recent Developments
- 4.3 Lyomark Pharma GmbH
- 4.3.1 Lyomark Pharma GmbH Company Information
- 4.3.2 Lyomark Pharma GmbH Business Overview
- 4.3.3 Lyomark Pharma GmbH Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Lyomark Pharma GmbH Somatostatin Product Portfolio
- 4.3.5 Lyomark Pharma GmbH Recent Developments
- 4.4 ALFA WASSERMANN S.p.A.
- 4.4.1 ALFA WASSERMANN S.p.A. Company Information
- 4.4.2 ALFA WASSERMANN S.p.A. Business Overview
- 4.4.3 ALFA WASSERMANN S.p.A. Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 ALFA WASSERMANN S.p.A. Somatostatin Product Portfolio
- 4.4.5 ALFA WASSERMANN S.p.A. Recent Developments
- 4.5 Polypeptide Laboratories, Inc
- 4.5.1 Polypeptide Laboratories, Inc Company Information
- 4.5.2 Polypeptide Laboratories, Inc Business Overview
- 4.5.3 Polypeptide Laboratories, Inc Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Polypeptide Laboratories, Inc Somatostatin Product Portfolio
- 4.5.5 Polypeptide Laboratories, Inc Recent Developments
- 4.6 SAMARTH
- 4.6.1 SAMARTH Company Information
- 4.6.2 SAMARTH Business Overview
- 4.6.3 SAMARTH Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SAMARTH Somatostatin Product Portfolio
- 4.6.5 SAMARTH Recent Developments
- 4.7 UBPL
- 4.7.1 UBPL Company Information
- 4.7.2 UBPL Business Overview
- 4.7.3 UBPL Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 UBPL Somatostatin Product Portfolio
- 4.7.5 UBPL Recent Developments
- 4.8 HYBIO
- 4.8.1 HYBIO Company Information
- 4.8.2 HYBIO Business Overview
- 4.8.3 HYBIO Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 HYBIO Somatostatin Product Portfolio
- 4.8.5 HYBIO Recent Developments
- 4.9 TianTaiShan
- 4.9.1 TianTaiShan Company Information
- 4.9.2 TianTaiShan Business Overview
- 4.9.3 TianTaiShan Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 TianTaiShan Somatostatin Product Portfolio
- 4.9.5 TianTaiShan Recent Developments
- 4.10 Yangtze River
- 4.10.1 Yangtze River Company Information
- 4.10.2 Yangtze River Business Overview
- 4.10.3 Yangtze River Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Yangtze River Somatostatin Product Portfolio
- 4.10.5 Yangtze River Recent Developments
- 4.11 Siyao
- 4.11.1 Siyao Company Information
- 4.11.2 Siyao Business Overview
- 4.11.3 Siyao Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Siyao Somatostatin Product Portfolio
- 4.11.5 Siyao Recent Developments
- 4.12 Shuangcheng
- 4.12.1 Shuangcheng Company Information
- 4.12.2 Shuangcheng Business Overview
- 4.12.3 Shuangcheng Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Shuangcheng Somatostatin Product Portfolio
- 4.12.5 Shuangcheng Recent Developments
- 4.13 Hainan Zhonghe
- 4.13.1 Hainan Zhonghe Company Information
- 4.13.2 Hainan Zhonghe Business Overview
- 4.13.3 Hainan Zhonghe Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Hainan Zhonghe Somatostatin Product Portfolio
- 4.13.5 Hainan Zhonghe Recent Developments
- 4.14 SL PHARM
- 4.14.1 SL PHARM Company Information
- 4.14.2 SL PHARM Business Overview
- 4.14.3 SL PHARM Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 SL PHARM Somatostatin Product Portfolio
- 4.14.5 SL PHARM Recent Developments
- 4.15 Wuhan Hualong
- 4.15.1 Wuhan Hualong Company Information
- 4.15.2 Wuhan Hualong Business Overview
- 4.15.3 Wuhan Hualong Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Wuhan Hualong Somatostatin Product Portfolio
- 4.15.5 Wuhan Hualong Recent Developments
- 4.16 Qingdao Guoda
- 4.16.1 Qingdao Guoda Company Information
- 4.16.2 Qingdao Guoda Business Overview
- 4.16.3 Qingdao Guoda Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Qingdao Guoda Somatostatin Product Portfolio
- 4.16.5 Qingdao Guoda Recent Developments
- 4.17 Chengdu Shengnuo
- 4.17.1 Chengdu Shengnuo Company Information
- 4.17.2 Chengdu Shengnuo Business Overview
- 4.17.3 Chengdu Shengnuo Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Chengdu Shengnuo Somatostatin Product Portfolio
- 4.17.5 Chengdu Shengnuo Recent Developments
- 4.18 Longjin
- 4.18.1 Longjin Company Information
- 4.18.2 Longjin Business Overview
- 4.18.3 Longjin Somatostatin Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Longjin Somatostatin Product Portfolio
- 4.18.5 Longjin Recent Developments
5 Global Somatostatin Market Scenario by Region
- 5.1 Global Somatostatin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Somatostatin Sales by Region: 2021-2032
- 5.2.1 Global Somatostatin Sales by Region: 2021-2026
- 5.2.2 Global Somatostatin Sales by Region: 2027-2032
- 5.3 Global Somatostatin Revenue by Region: 2021-2032
- 5.3.1 Global Somatostatin Revenue by Region: 2021-2026
- 5.3.2 Global Somatostatin Revenue by Region: 2027-2032
- 5.4 North America Somatostatin Market Facts & Figures by Country
- 5.4.1 North America Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Somatostatin Sales by Country (2021-2032)
- 5.4.3 North America Somatostatin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Somatostatin Market Facts & Figures by Country
- 5.5.1 Europe Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Somatostatin Sales by Country (2021-2032)
- 5.5.3 Europe Somatostatin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Somatostatin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Somatostatin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Somatostatin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Somatostatin Market Facts & Figures by Country
- 5.7.1 South America Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Somatostatin Sales by Country (2021-2032)
- 5.7.3 South America Somatostatin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Somatostatin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Somatostatin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Somatostatin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Somatostatin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Somatostatin Sales by Type (2021-2032)
- 6.1.1 Global Somatostatin Sales by Type (2021-2032) & (K Pcs)
- 6.1.2 Global Somatostatin Sales Market Share by Type (2021-2032)
- 6.2 Global Somatostatin Revenue by Type (2021-2032)
- 6.2.1 Global Somatostatin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Somatostatin Revenue Market Share by Type (2021-2032)
- 6.3 Global Somatostatin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Somatostatin Sales by Application (2021-2032)
- 7.1.1 Global Somatostatin Sales by Application (2021-2032) & (K Pcs)
- 7.1.2 Global Somatostatin Sales Market Share by Application (2021-2032)
- 7.2 Global Somatostatin Revenue by Application (2021-2032)
- 7.2.1 Global Somatostatin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Somatostatin Revenue Market Share by Application (2021-2032)
- 7.3 Global Somatostatin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Somatostatin Value Chain Analysis
- 8.1.1 Somatostatin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Somatostatin Production Mode & Process
- 8.2 Somatostatin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Somatostatin Distributors
- 8.2.3 Somatostatin Customers
9 Global Somatostatin Analyzing Market Dynamics
- 9.1 Somatostatin Industry Trends
- 9.2 Somatostatin Industry Drivers
- 9.3 Somatostatin Industry Opportunities and Challenges
- 9.4 Somatostatin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst